The company said, “Reaffirming full year 2025 net product revenue of $820 million to $860 million.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences reports Q2 adjusted EPS 92c, consensus 96c
- 3 Best Stocks to Buy Now, 7/29/2025, According to Top Analysts
- Harmony Biosciences Holdings: Promising Growth Trajectory with Strong Leadership and Robust Pipeline Supports Buy Rating
- Harmony Biosciences initiated with a Buy at Truist
- Buy Rating Reaffirmed for Harmony Biosciences Amid Promising Orexin-2 Developments and Takeda’s Phase 3 Success